Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 9/20 | 0.58 |
| ▸ | CCR3 | P51677 | 9/20 | 0.56 |
| ▸ | DRD2 | P14416 | 8/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102629 | 0.85 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL26306413 | 0.84 | DRD2 (0.58) | DRD2 | |
| SCHEMBL24813962 | 0.82 | DRD2 (0.55) | DRD2KCNH2 | |
| SCHEMBL5658226 | 0.80 | DRD2 (0.49) | HRH1CCR3DRD2 | |
| Acetic Acid SCHEMBL5656726 | 0.80 | CCR3 (0.69) | HRH1CCR3DRD2KCNH2 | |
| SCHEMBL5363961 | 0.79 | CCR3 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL5657070 | 0.79 | CCR3 (0.67) | HRH1CCR3KCNH2 | |
| SCHEMBL13176904 | 0.78 | CCR3 (0.61) | HRH1CCR3DRD2KCNH2 | |
| SCHEMBL13177091 | 0.78 | HRH1 (0.54) | HRH1CCR3KCNH2 | |
| SCHEMBL19852276 | 0.78 | DRD2 (0.52) | CCR3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-20040102432-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1412330-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| EP-1322611-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2003018556-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002020484-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102432-A1 | Chemical compounds | CCL11, HRH1, HRH4 | HRH1 2/4885CCR3 17/4885DRD2 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.